Glumetinib
CAS No. : 1642581-63-2
(Synonyms: Gumarontinib; SCC244)
| Size | Price | Stock |
|---|---|---|
| 5mg | $135 | In-stock |
| 10mg | $205 | In-stock |
| 50mg | $520 | In-stock |
| 100mg | $775 | In-stock |
| 200 mg | Get quote | |
| 500 mg | Get quote | |
| We match the lowest price on market. | ||
We offer a substantial discount on larger orders, please inquire via [email protected]
or Fax: (86)21-58955996
Inquiry for price and availability only. Please place your order via our email or fax.
| Cat. No. : | HY-116000 |
| M.Wt: | 459.48 |
| Formula: | C21H17N9O2S |
| Purity: | >98 % |
| Solubility: | DMSO : 41.67 mg/mL (ultrasonic) |
Glumetinib (SCC244) is a highly selective, orally bioavailable, ATP-competitive c-Met inhibitor with an IC50 of 0.42 nM. Glumetinib has greater than 2400-fold selectivity for c-Met over those 312 kinases evaluated, including the c-Met family member RON and highly homologous kinases Axl, Mer, TyrO3. Antitumor activity[1].
IC50 & Target:IC50: 0.42 nM (c-Met kinase)[1]
In Vitro: Glumetinib (SCC244) (0-10 nM; 72 hours) elicits selective and profound effects against c-Met–driven cancer cell proliferation[1].
Glumetinib (0-50 nM; 24 hours) induces G1–S phase cell-cycle arrest in c-Met–addicted human cancer cells[1].
In Vivo: Glumetinib (2.5-10 mg/kg; p.o.; once daily for 2-3 weeks) significantly inhibits c-Met–driven tumor growth in cancer CDX models[1].
Glumetinib shows significant antitumor efficiency in NSCLC and HCC tumor PDX models with MET aberration[1].
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Autem earum hic iste maiores, nam neque rem suscipit. Adipisci consequatur error exercitationem fugit ipsam optio qui, quibusdam repellendus sed vero! Debitis.
Inquiry Information- Product Name:
- Glumetinib
- Cat. No.:
- HY-116000
- Quantity:
Your information is safe with us.